In addition to expression of Shh, Ptch1, and Gli1, BCL-2 levels are also upregulated in CML cell lines, and the inhibition of both Shh and BCL-2 could make leukemic cells more sensitive to imatinib [30]. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.